Cedars-Sinai researchers find two potential treatments that improve outcomes in recurrent prostate cancer

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Blood test predicts prognosis for advanced prostate cancer, study finds

A new study, published in Nature Communications and led by the University of Minnesota Medical School and Duke University, found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the blood of certain patients with advanced, metastatic prostate cancer.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.

December 06, 2024

Vol.50 No.45

Health Equity

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.

November 22, 2024

Vol.50 No.44

By McKenzie Prillaman

In Brief

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Jupiter Bioventures, a biotechnology venture foundry that builds science-driven therapeutics companies, announced the closing of a $70 million initial financing.

November 22, 2024

Vol.50 No.44

In Brief

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

TD Bank has committed $100,000 to support the MUSC Hollings Cancer Center’s SC AMEN program, a community outreach initiative that brings education, screenings, and health services assistance to Black men 40 to 69 years old in South Carolina.

November 22, 2024

Vol.50 No.44

Cedars-Sinai researchers find two potential treatments that improve outcomes in recurrent prostate cancer

YOU MAY BE INTERESTED IN

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

Blood test predicts prognosis for advanced prostate cancer, study finds

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

Renew today!

Subscriber content

Never miss an issue!

Login